Who Owns Tyvaso?

As a specialized pharmaceutical product, Tyvaso's sustainability considerations focus on responsible manufacturing, patient access, and environmental compliance.

Manufacturing: United Therapeutics implements sustainable manufacturing practices focusing on energy-efficient production processes, water conservation, and waste reduction at its U.S. manufacturing facilities.

Patient Access: United Therapeutics operates the Tyvaso Access Solutions program to help eligible patients navigate insurance coverage and financial assistance options. The program includes financial assistance, copay support, and patient education services.

Environmental Compliance: Tyvaso's manufacturing facilities comply with environmental regulations for pharmaceutical production, including proper handling of chemical substances, waste management protocols, and emissions controls.

Clinical Trial Ethics: Tyvaso's development followed ethical standards for clinical research, including informed consent processes, independent data monitoring committees, and transparent reporting. The TETON-2 results were published in the New England Journal of Medicine.

High Cost and Access Barriers: Tyvaso's annual treatment cost can exceed $100,000 in the United States, creating access barriers for patients without adequate prescription drug coverage. The high price has been subject to criticism from patient advocacy groups and healthcare payers.

• FDA First Inhaled Prostacyclin (2009): Tyvaso was the first inhaled prostacyclin therapy approved for pulmonary arterial hypertension, establishing a new treatment paradigm.
• First Approved Therapy for PH-ILD (2021): The April 2021 FDA approval for PH-ILD made Tyvaso the first approved therapy specifically for this condition, addressing significant unmet medical need.
• TETON-2 Published in New England Journal of Medicine: The TETON-2 study results for Nebulized Tyvaso in IPF were published in the New England Journal of Medicine, demonstrating a 48 percent reduction in acute exacerbation risk.
• Record Revenue Growth (2025): United Therapeutics achieved its fourth consecutive year of record total revenue in 2025, with Total Tyvaso revenue growing 16 percent to $1.88 billion.

Competitive Pressure on Nebulized Tyvaso: United Therapeutics stated in Q2 2026 that the availability of competitive therapies negatively impacted sales of Nebulized Tyvaso, Tyvaso DPI, and Remodulin. Nebulized Tyvaso revenue declined 18 percent year-over-year in Q2 2026, driven by a decrease in U.S. quantities sold of $37.6 million.

Treatment Adherence Challenges: Tyvaso's dosing regimen of 4 inhalations 4 times daily during waking hours creates adherence challenges for patients. The time-intensive treatment schedule can be difficult to maintain consistently, potentially affecting treatment effectiveness.

Side Effects: Tyvaso is associated with common side effects including cough, headache, nausea, dizziness, and throat irritation, which can limit tolerability and adherence in some patients.

High Cost and Access Barriers: Tyvaso's annual treatment cost can exceed $100,000 in the United States, creating significant access barriers for patients without adequate prescription drug coverage. The high price has been subject to criticism from patient advocacy groups and healthcare payers.

Dosing Complexity: The complex dosing schedule and requirement for multiple daily inhalations create treatment burden for patients and caregivers, particularly for elderly patients or those with cognitive limitations.

Limited Indication for PAH: Tyvaso's approved indication for PAH is limited to patients receiving background oral therapy with an endothelin receptor antagonist or a phosphodiesterase type 5 inhibitor, restricting its use as monotherapy.